New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the initial phase II study of MIV-711, which demonstrated disease-modifying activity in patients with moderate knee osteoarthritis after only six months of treatment, will be presented during the American College of Rheumatology (ACR) annual meeting, which will take place from 19-24 October 2018 in Chicago, USA. The presentation will be given by the study’s lead investigator Dr. Philip Conaghan, Professor of Musculoskeletal Medicine at the University of Leeds in the UK, and will be made on Sunday